Concert Pharmaceuticals Inc (NASDAQ:CNCE) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a note issued to investors on Monday.

According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “

Several other analysts have also commented on CNCE. Stifel Nicolaus reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Concert Pharmaceuticals in a report on Wednesday, April 5th. Aegis reiterated a “buy” rating and set a $25.00 target price on shares of Concert Pharmaceuticals in a research report on Wednesday, April 5th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $26.40.

Concert Pharmaceuticals (NASDAQ:CNCE) traded down 2.98% on Monday, reaching $14.97. The company’s stock had a trading volume of 126,033 shares. The company’s 50 day moving average price is $16.43 and its 200-day moving average price is $11.58. Concert Pharmaceuticals has a 12-month low of $7.11 and a 12-month high of $19.11. The stock’s market cap is $337.75 million.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by $0.06. The business earned $0.02 million during the quarter. Concert Pharmaceuticals had a negative return on equity of 33.68% and a negative net margin of 363.29%. On average, equities analysts expect that Concert Pharmaceuticals will post ($1.65) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/08/concert-pharmaceuticals-inc-cnce-downgraded-to-sell-at-zacks-investment-research.html.

Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in shares of Concert Pharmaceuticals by 0.4% in the third quarter. Wells Fargo & Company MN now owns 32,135 shares of the biotechnology company’s stock worth $324,000 after buying an additional 136 shares during the last quarter. Rockefeller Financial Services Inc. raised its stake in Concert Pharmaceuticals by 19.6% in the first quarter. Rockefeller Financial Services Inc. now owns 10,289 shares of the biotechnology company’s stock worth $176,000 after buying an additional 1,689 shares in the last quarter. GSA Capital Partners LLP raised its stake in Concert Pharmaceuticals by 6.0% in the fourth quarter. GSA Capital Partners LLP now owns 56,309 shares of the biotechnology company’s stock worth $579,000 after buying an additional 3,204 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Concert Pharmaceuticals by 4.1% in the first quarter. Bank of New York Mellon Corp now owns 124,144 shares of the biotechnology company’s stock worth $2,118,000 after buying an additional 4,873 shares in the last quarter. Finally, Highbridge Capital Management LLC raised its stake in Concert Pharmaceuticals by 46.4% in the fourth quarter. Highbridge Capital Management LLC now owns 15,677 shares of the biotechnology company’s stock worth $161,000 after buying an additional 4,967 shares in the last quarter. Hedge funds and other institutional investors own 60.37% of the company’s stock.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

5 Day Chart for NASDAQ:CNCE

Get a free copy of the Zacks research report on Concert Pharmaceuticals (CNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.